Royalty Pharma expects 2024 Portfolio Receipts to be between $2,600 million and $2,700 million. 2024 Portfolio Receipts guidance includes expected growth in Royalty Receipts of 5% to 9%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
- Arrowhead earns $50M milestone from Royalty Pharma
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
- Royalty Pharma Declares Second Quarter 2024 Dividend
- Royalty Pharma price target lowered to $38 from $40 at BofA